Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duramed Planning Cenestin DTC Ad Campaign With Marketing Partner

Executive Summary

Duramed is planning a direct-to-consumer ad campaign with an undisclosed marketing partner for its synthetic conjugated estrogens product Cenestin, approved on March 24 for treatment of moderate-to-severe vasomotor symptoms associated with menopause.

You may also be interested in...



Wyeth Premarin Market-Share Rebates Challenged In Duramed Antitrust Suit

Wyeth-Ayerst's Premarin market share-based rebates represent an antitrust violation, Duramed maintained in a lawsuit filed Sept. 5 in Cincinnati federal court.

Wyeth Premarin Market-Share Rebates Challenged In Duramed Antitrust Suit

Wyeth-Ayerst's Premarin market share-based rebates represent an antitrust violation, Duramed maintained in a lawsuit filed Sept. 5 in Cincinnati federal court.

Duramed Cenestin DTC Ads Aim To Chill Premarin With New, "Cool" Message

Duramed's Cenestin (synthetic conjugated estrogens, A) direct-to-consumer print ad campaign emphasizes the plant-source of the product as an alternative to Wyeth-Ayerst's equine-derived Premarin.

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel